title: Lipoprotein Apheresis.
abstract: Patients with familial hypercholesterolemia (FH) have early development of atherosclerosis and cardiovascular disease (CVD). Lipid level-lowering medications are not always successful in reducing increased low-density lipoprotein C (LDL-C) levels. Lipoprotein apheresis (LA) therapy has proven its clinical benefit in reducing CVD events for patients with FH with hypercholesterolemia. LA reduces LDL-C levels by more than 60% in patients with FH and reduces CVD events. LA also reduces Lp(a) levels and CVD events. LA reduces inflammatory markers and blood viscosity.
authors.affiliation: Division of Clinical Pharmacology and Atherosclerosis/Lipoprotein-Apheresis Center, University of Kansas Medical Center, 3901 Rainbow Boulevard, Mail Stop 3008, Kansas City, KS 66160, USA. Electronic address: pmoriart@kumc.edu.
authors.forename: Patrick M
authors.initials: PM
authors.lastname: Moriarty
authors.affiliation: Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA.
authors.forename: Linda
authors.initials: L
authors.lastname: Hemphill
keywords: Atherosclerosis; CVD; Familial hypercholesterolemia; LDL-C; Lipoprotein apheresis; Lp(a)